Abstract 505P
Background
The RATIONALE-312 study reports PD-1 inhibitor (tislelizumab) plus platinum–etoposide could improve survival of patients with extensive-stage small-cell lung cancer (SCLC). Based on this, we initiated a pilot study to explore the safety and feasibility of neoadjuvant Tislelizumab plus platinum–etoposide in limited-stage SCLC.
Methods
Treatment-naïve limited-stage SCLC patients with ECOG PS 0-1 status were enrolled. Patients received 4 cycles of Tislelizumab (200mg, q3w) plus platinum (Cisplatin 75 mg/m2 or Carboplatin AUC5) – etoposide (100 mg/m2). The feasibility of surgery was then reassessed by radiology. Candidates for complete resection underwent surgery; otherwise, they received radiotherapy. Patients who received surgery also received adjuvant Tislelizumab plus platinum–etoposide therapy for 4 cycles. Primary endpoints were safety and feasibility. Secondary endpoints were objective response rate (ORR), pathologic response, and survival.
Results
A total of 8 eligible patients were enrolled up to April 2023. The median age was 65 (range: 57-70) with 6 male patients and 7 smokers. Among them, 1, 4, and 3 patients had stage ⅡB, ⅢA and ⅢB disease, respectively. No previously unreported toxic effects were observed. Treatment-related adverse events (TRAEs) of any grade occurred in 7 of 8 (87.5%) patients. Grade 3-4 events occurred in 6 of 8 (75%) patients. There were no severe adverse events. The majority of TRAEs was chemotherapy-related, and 2 patients suffered mild immune-related thyroid dysfunction. Seven patients completed 4 cycles of neoadjuvant therapy, and the best ORR was 85.7% (5 partial response and 1 stable disease). Of the 7 patients, 5 were assessed to be resectable. There were no treatment-related surgical delays. R0 resection and pathological downstaging were achieved for all 5 patients (100%) without any serious surgical complications. At a median of 18 months (range: 10 - 20) of follow-up, all patients were alive, and all the patients who received surgery were recurrence-free.
Conclusions
Neoadjuvant Tislelizumab plus platinum–etoposide was associated with tolerable side effects and was effective for patients with limited-stage SCLC.
Clinical trial identification
NCT04542369.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Pulmonary Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract